1. Home
  2. HYNE vs ANIX Comparison

HYNE vs ANIX Comparison

Compare HYNE & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hoyne Bancorp Inc.

HYNE

Hoyne Bancorp Inc.

HOLD

Current Price

$17.51

Market Cap

122.6M

Sector

Finance

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.75

Market Cap

114.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HYNE
ANIX
Founded
2025
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
122.6M
114.0M
IPO Year
2025
2013

Fundamental Metrics

Financial Performance
Metric
HYNE
ANIX
Price
$17.51
$2.75
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $9.75
AVG Volume (30 Days)
8.0K
★ 229.4K
Earning Date
11-08-2026
09-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 12.82
EPS
★ N/A
N/A
Revenue
N/A
★ $210,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.56
$2.32
52 Week High
$17.26
$5.46

Technical Indicators

Market Signals
Indicator
HYNE
ANIX
Relative Strength Index (RSI) 83.29 43.58
Support Level $16.31 $2.62
Resistance Level N/A $3.09
Average True Range (ATR) 0.18 0.13
MACD 0.07 -0.00
Stochastic Oscillator 74.63 21.57

Price Performance

Historical Comparison
HYNE
ANIX

About HYNE Hoyne Bancorp Inc.

Hoyne Bancorp Inc is a holding company that conducts business mainly through its subsidiaries. It is a savings institution focused on serving customers' banking needs in the market area. The group offers Personal and Business banking services.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: